Actelion

Actelion Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland. Its first drug, Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension and is marketed through its own subsidiaries in key markets worldwide including the U.S., E.U., Japan, Canada, Australia and Switzerland. Founded in 1997, Actelion is a leading player in innovative science related to the endothelium and has over 2,500 employees focused on the discovery, development, and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange as part of the Swiss blue-chip index SMI.